Portal de Periódicos da CAPES

Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies)

2022; American Society for Microbiology; Volume: 10; Issue: 5 Linguagem: Inglês

10.1128/spectrum.02927-22

2165-0497

Marta Hernández-García, María García-Castillo, Germán Bou, Emilia Cercenado, Mercedes Delgado-Valverde, Antonio Oliver, Cristina Pitart, Jesús Rodríguez‐Lozano, Nuria Tormo, José Melo‐Cristino, Margarida Pinto, Elsa Gonçalves, Valquíria Alves, Ana Raquel Vieira, Elmano Ramalheira, Luísa Sancho, José Diogo, Rui M. Ferreira, Hugo Cruz, Catarina Chaves, Joana Duarte, Leonor Pássaro, Jazmín Díaz-Regañón, Rafael Cantón,

Antibiotic Use and Resistance

We comparatively evaluate the in vitro activity of a drug combination consisting of a carbapenem (imipenem) and a novel inhibitor of beta-lactamases (relebactam), a mechanism that destroys beta-lactam antibiotics. We assess the activity against a collection of Enterobacterales clinical isolates recovered from difficult-to-treat infections in patients admitted to different intensive care units in Portugal and Spain.